FORM 4

Check this box if no longer subject to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSI	ΗP
--	----

	OMB APPROVAL										
	OMB Number:	3235-0287									
	Estimated average bur	den									
ı	hours per response:	0.5									

Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Weber Darin J.						2. Issuer Name and Ticker or Trading Symbol PROKIDNEY CORP. [PROK]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last)	(F OKIDNEY (irst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 02/05/2024								X Officer (give title Other (specify below) SVP of Regulatory Development				
2000 FRONTIS PLAZA BLVD, SUITE 250					4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) WINSTO	DN- N	C	27103		В	···lo	10h	5 1(0)	Trans	a cti	on Ind	ication		_	ed by More	Reporting Person		
(City) (State) (Zip)						Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
		Та	ble I - Nor	n-Deri	ivativ	/e Se	curi	ities Ac	quired,	Dis	posed o	of, or Be	neficiall	y Owned				
1. Title of Security (Instr. 3) 2. Trans. Date (Month/L				/Day/Year) i		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed Code (Instr.		ties Acquired (A) or d Of (D) (Instr. 3, 4 and		Beneficia Owned F	s F Ily (I	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) (D)	Price	Reported Transacti (Instr. 3 a	ion(s)		(Instr. 4)		
Class A C	Ordinary Sh	ares		02/0	05/202	/2024 C 137,073 A		\$0	274,073		D							
			Table II -									, or Ben ble secu		Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise (Month/Day/Year) 3. Transaction Date (Execution Date, if any (Month/Day/Year) 3. Deemed Execution Date, if any (Month/Day/Year)		ate, T	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	n(s)		
Class B Ordinary Shares ⁽¹⁾	\$0	02/05/2024			С			137,073	(2)		(2)	Class A Ordinary Shares	137,073	\$0	402,283	D		
Common Units in ProKidney LP ⁽¹⁾	\$0	02/05/2024			С			137,073	(3)		(3)	Class A Ordinary Shares	137,073	\$0	402,283	D		

Explanation of Responses:

- 1. The Class B Ordinary Shares and the Common Units in ProKidney LP (a "Common Unit") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for Class A Ordinary Shares on a one-for-one basis.
- 2. The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire.
- 3. The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.

/s/ Todd Girolamo, as Attorney-in-Fact

02/06/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.